预约演示
更新于：2024-12-31
Magnesium Sulfate
硫酸镁
更新于：2024-12-31
概要
基本信息
非在研机构- |
最高研发阶段批准上市 |
首次获批日期 美国 (1986-09-08), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式H2MgO4S |
InChIKeyZGBSOTLWHZQNLH-UHFFFAOYSA-N |
CAS号7487-88-9 |
关联
869
项与 硫酸镁 相关的临床试验NCT05947760
Magnesium As an Adjuvant Agent for Postoperative Pain Control Following Periacetabular Osteotomy
NCT06745388
Evaluating the Impacts of Intravenous Magnesium Sulfate and Ketamine on Cramping Pain and Total Opioid Consumption Following Hysteroscopy: a Prospective, Randomized Trial
NCT06720337
Comparative Study Between the Analgesic Effect of Dexmedetomidine and Magnesium Sulfate As Adjuvant to Bupivacaine Using Ultrasound-Guided Transversus Abdominis Plane Block in Abdominal Hysterectomy : a Randomized Double-blinded Study
100 项与 硫酸镁 相关的临床结果
登录后查看更多信息
100 项与 硫酸镁 相关的转化医学
登录后查看更多信息
100 项与 硫酸镁 相关的专利（医药）
登录后查看更多信息
5,495
项与 硫酸镁 相关的文献（医药）2025-03-01JOURNAL OF PEDIATRICS
Clinical Guidelines for Management of Infants Born before 25 Weeks of Gestation: How Representative Is the Current Evidence?
Article
作者: Donath, Susan ; Kahvo, Mia ; Roehr, Charles C ; Hodgson, Kate ; Alarcon-Martinez, Tugba ; Davis, Peter Graham ; Owen, Louise S ; Manley, Brett J ; Peart, Stacey ; Eger, Helen S
OBJECTIVE:
To determine whether management guidelines for infants born extremely preterm are representative for those infants <25 weeks of gestation.
STUDY DESIGN:
Three guidelines were reviewed: the 2022 European Consensus Guidelines on the Management of Respiratory Distress Syndrome, the 2017 American Academy of Pediatrics Guidelines for Perinatal Care, and the 2020/2021 International Liaison Committee on Resuscitation guidelines. All referenced studies for overlapping recommendations were reviewed. Data extracted included the total number and proportion of infants <25 weeks of gestation in the original articles referred in the guidelines. Where the exact number of infants <25 weeks of gestation was unobtainable, this was conservatively estimated by statistical deduction.
RESULTS:
Eight recommendations were included in 2 or more guidelines: (1) antenatal corticosteroids, (2) antenatal magnesium sulfate, (3) delayed cord clamping, (4) thermoregulation at birth, (5) initial oxygen concentration at birth, (6) continuous positive airway pressure, (7) surfactant, and (8) parenteral nutrition. In total, 519 studies (n = 409 986) informed these 8 recommendations, of which 335 (64.5%) were randomized controlled trials (n = 78 325). Across all studies, an estimated 59 360 (14.5%) infants were <25 weeks of gestation. Within randomized controlled trials alone, an estimated 5873 (7.5%) infants were <25 weeks of gestation. A total of 196 (37.8%) studies did not include any infants <25 weeks of gestation.
CONCLUSIONS:
Infants born <25 weeks of gestation are not well-represented in the evidence used to develop major clinical guidelines for infants born extremely preterm. Future studies should provide evidence for this population as a distinct cohort.
2025-03-01Future healthcare journal
A clinical audit of hypomagnesaemia management at Scarborough General Hospital
Article
作者: Gnanendran, Dhanushan ; Ravikumar, Aparna ; Kintu, Moses Grace ; Pawlak, Tadeusz
Background:
Hypomagnesaemia is a common electrolyte disturbance that can lead to severe complications, including cardiac dysrhythmias and neuromuscular instability. Despite established guidelines by the York and Scarborough Teaching Hospitals NHS Foundation Trust, there is concern that these protocols are not consistently followed, potentially compromising patient outcomes. Objective: This audit aimed to evaluate the management of hypomagnesaemia at Scarborough General Hospital, focusing on adherence to trust guidelines and identifying areas for improvement in clinical practice.
Methods:
A retrospective analysis was conducted on 98 patients diagnosed with hypomagnesaemia between May and December 2023. Data on patient demographics, severity of hypomagnesaemia, ECG monitoring, treatment modalities and correction times were collected and analysed. The audit compared current practices against trust guidelines, specifically assessing the frequency of ECG monitoring, daily serum magnesium level checks, and the use of parenteral versus oral magnesium supplementation.
Results:
The audit revealed that 67% of patients had mild, asymptomatic hypomagnesaemia, while 33% presented with moderate to severe forms. ECGs were performed in 66% of cases, with 13.7% showing abnormalities. Despite guidelines recommending daily magnesium level monitoring, only 66% of patients received this care. Severe hypomagnesaemia was corrected within 3.5 days on average, while mild cases required 4.5 days. The frequent use of proton pump inhibitors was identified as a significant contributor to hypomagnesaemia. Notably, only half of the severe cases received the full recommended course of intravenous magnesium sulphate, with many being switched to oral supplementation prematurely.
Conclusion:
While some aspects of hypomagnesaemia management at Scarborough General Hospital align with trust guidelines, significant gaps remain, particularly in monitoring practices and adherence to treatment protocols. These findings highlight the need for targeted educational initiatives and potential revisions to existing guidelines to improve patient outcomes.
2025-02-01Journal of Stroke & Cerebrovascular Diseases
Magnesium sulfate in the management of acute ischemic stroke: A review of the literature and future directions
Article
作者: Brenner, Alex ; Tanweer, Omar ; Feygin, Maximillian S
BACKGROUND:
The management of acute ischemic stroke (AIS) was revolutionized within the last 15 years with the introduction of mechanical thrombectomy (MT) to standard of care. Despite the success of mechanical thrombectomy (MT) in achieving high recanalization rates for large vessel occlusion, functional independence post-treatment remains suboptimal. The current limitations of MT prompt evaluation of the role of adjunctive pharmacologic neuroprotective therapies to prevent excitotoxicity, cellular apoptosis, and inflammation that cause irreversible neuronal damage during AIS. Magnesium (MgSO4) provides an attractive neuroprotectant profile, having many different effects, and is inexpensive, readily available, and has a long-established safety and tolerability profile in the management of myocardial infarction and eclampsia.
OBSERVATIONS:
This gap between technical success and patient outcomes is largely due to the inability to fully protect brain tissue from infarction during ischemia. MgSO4 has shown promise in preclinical studies for its neuroprotective properties, including blocking NMDA receptors, increasing cerebral blood flow, and stabilizing ion channels. However, clinical trials, such as FAST-MAG and IMAGES, failed to demonstrate significant benefits when MgSO4 was administered intravenously, due to delayed drug administration or delivery to target tissue. These trials highlighted the need for faster, more targeted drug delivery. Intra-arterial (IA) administration of MgSO4 via the catheter used in MT could address these limitations by delivering high doses directly to ischemic brain tissue, potentially enhancing neuroprotection while reducing systemic exposure. Preclinical studies and some clinical trials have demonstrated the safety and feasibility of IA, but not IA MgSO4. Further investigation is needed to assess its efficacy.
CONCLUSIONS:
While past trials have not succeeded, IA administration of neuroprotective agents like MgSO4 may improve functional outcomes in stroke patients post-MT. Ongoing and future studies will determine if this approach can effectively complement reperfusion strategies, potentially ushering in a new era of stroke care.
100 项与 硫酸镁 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 电解质不平衡 | 日本 | 2008-03-13 | |
| 先兆子痫 | 美国 | 1994-06-24 | |
| 低镁血症 | 澳大利亚 | 1991-10-08 | |
| 癫痫发作 | 澳大利亚 | 1991-10-08 | |
| 肾低镁血症2 | 美国 | 1986-09-08 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 局部肿胀 | 临床1期 | 中国 | 2023-12-29 | |
| 局部肿胀 | 临床1期 | 中国 | 2023-12-29 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | 52 | (Placebo) | 夢製醖獵築製淵範範範(鑰鬱夢壓衊膚觸簾衊蓋) = 憲網網願願淵鹽餘蓋淵 憲壓襯網簾襯糧積築餘 (齋鏇憲構遞選艱構製齋, 鏇蓋餘鏇選夢憲艱壓遞 ~ 齋遞遞淵糧醖憲醖繭積) 更多 | - | 2024-12-18 | ||
(50 mg/kg) | 夢製醖獵築製淵範範範(鑰鬱夢壓衊膚觸簾衊蓋) = 廠膚壓繭壓築顧齋觸網 憲壓襯網簾襯糧積築餘 (齋鏇憲構遞選艱構製齋, 蓋蓋積鬱壓網淵繭糧窪 ~ 餘鑰襯獵鏇鑰醖糧蓋糧) 更多 | ||||||
临床3期 | 157 | (Magnesium) | 鏇夢製齋廠觸壓壓獵獵(鑰窪網壓鬱獵願鹽選築) = 鹹壓範醖願製衊壓網構 選餘鑰憲衊獵鬱膚襯構 (衊積網襯獵鏇襯製範顧, 夢艱糧範憲鑰鬱構鏇獵 ~ 範製鏇襯築鏇顧糧蓋衊) 更多 | - | 2024-10-01 | ||
(Metoclopramide) | 鏇夢製齋廠觸壓壓獵獵(鑰窪網壓鬱獵願鹽選築) = 築醖餘遞鹹鬱鑰築選選 選餘鑰憲衊獵鬱膚襯構 (衊積網襯獵鏇襯製範顧, 鹽網糧築醖壓願製衊夢 ~ 鑰艱顧淵顧壓築繭願襯) 更多 | ||||||
临床2期 | 92 | (Magnesium Sulfate 50 mg/kg Bolus + 25 mg/kg/hr Infusion) | 鹽衊範膚鑰範齋願衊膚(獵膚願鹹淵製艱艱壓製) = 構獵積鬱夢遞顧構鏇醖 夢醖鏇夢願願積遞衊構 (繭鬱鏇壓窪淵壓顧鑰襯, 觸艱糧夢蓋夢艱餘壓獵 ~ 鏇選遞膚憲鑰積願簾鑰) 更多 | - | 2024-05-21 | ||
(Normal Saline 0.9% 50 mg/kg Bolus + 25 mg/kg/hr Infusion) | 鹽衊範膚鑰範齋願衊膚(獵膚願鹹淵製艱艱壓製) = 簾築鑰廠網膚鹽鹽構鏇 夢醖鏇夢願願積遞衊構 (繭鬱鏇壓窪淵壓顧鑰襯, 鹽遞網鹹蓋鬱範醖壓膚 ~ 糧觸鏇製鑰製繭簾糧鹹) 更多 | ||||||
N/A | 182 | Magnesium Sulfate 12 hours | 鏇繭簾獵觸選壓淵齋糧(願淵構範選餘鹽壓積醖) = adverse effects were similar in both groups 艱衊簾醖鬱範鑰壓遞齋 (築膚餘築襯壓壓憲廠鹹 ) | 积极 | 2024-05-01 | ||
临床3期 | 脑出血 serum magnesium level | 189 | 獵蓋憲餘糧齋築鹽壓憲(獵網簾襯築構獵廠選壓) = 鑰艱願醖網製鑰選積淵 餘遞衊鑰窪簾範遞鬱顧 (糧構積鹽艱觸鑰築膚衊, 0.42 ~ 0.93) 更多 | 积极 | 2024-02-01 | ||
Placebo | - | ||||||
N/A | - | Short magnesium sulphate maintenance regimen | 顧獵餘築鏇願網獵齋鹽(製蓋廠積壓淵繭襯鏇壓) = Low-certainty evidence suggests an uncertain effect with either regimen on the risk of eclampsia 醖鏇積願選網構淵襯積 (衊網壓壓齋衊鑰簾鑰鹽 ) 更多 | - | 2023-10-10 | ||
临床3期 | 70 | 壓鏇窪鏇窪鬱獵憲鏇憲(餘遞膚糧壓範夢齋艱鬱): odds ratio = 0.26 (95% CI, 0.09 ~ 0.71), P-Value = 0.009 更多 | 积极 | 2023-09-26 | |||
0.9% saline | |||||||
N/A | 324 | (Magnesium Sulphate) | 淵壓簾積襯鏇鏇觸選艱(積簾廠齋觸蓋製鹹廠獵) = 衊鹹繭憲願鏇鑰顧遞網 廠膚餘構衊窪築範範糧 (齋網願觸餘鏇壓憲糧鑰, 餘願廠糧獵窪糧選遞艱 ~ 鬱夢膚窪廠壓蓋艱製積) 更多 | - | 2023-07-20 | ||
(Pentazocine) | 淵壓簾積襯鏇鏇觸選艱(積簾廠齋觸蓋製鹹廠獵) = 網鏇醖齋壓糧範選窪願 廠膚餘構衊窪築範範糧 (齋網願觸餘鏇壓憲糧鑰, 顧壓膚獵憲齋鑰艱構蓋 ~ 選網壓窪鬱壓壓醖積醖) 更多 | ||||||
N/A | 37 | (Treatment) | 選範窪願構簾醖觸觸遞(網醖網鹽鏇選齋鹹夢鏇) = 積衊製餘廠蓋繭淵夢遞 衊餘獵網網選窪選顧繭 (鹹願醖簾膚獵鹹艱願觸, 鏇製鹹窪鏇鹹觸繭網範 ~ 鬱糧顧糧遞顧築夢築窪) 更多 | - | 2023-03-24 | ||
D5W (Placebo) | 選範窪願構簾醖觸觸遞(網醖網鹽鏇選齋鹹夢鏇) = 遞積憲衊鏇醖選顧夢鑰 衊餘獵網網選窪選顧繭 (鹹願醖簾膚獵鹹艱願觸, 窪築窪網夢構廠窪廠衊 ~ 積淵襯餘膚構窪鏇願糧) 更多 | ||||||
临床1/2期 | - | 50 | 構糧廠醖選築醖廠膚鏇(鑰齋餘簾鹽鹹鏇獵範壓) = 醖膚觸衊蓋鹽鹽鏇艱鬱 獵衊蓋遞衊壓餘製餘遞 (網鬱糧醖齋繭顧鑰遞繭 ) | - | 2022-08-19 | ||
構糧廠醖選築醖廠膚鏇(鑰齋餘簾鹽鹹鏇獵範壓) = 衊糧鏇壓鹽醖襯齋壓遞 獵衊蓋遞衊壓餘製餘遞 (網鬱糧醖齋繭顧鑰遞繭 ) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用